Home  |  Contact

Cellosaurus BV-173/E255K (CVCL_5K95)

[Text version]

Cell line name BV-173/E255K
Synonyms BV173/E255K
Accession CVCL_5K95
Resource Identification Initiative To cite this cell line use: BV-173/E255K (RRID:CVCL_5K95)
Comments Selected for resistance to: ChEBI; CHEBI:45783; Imatinib (Gleevec; STI571).
Derived from sampling site: Peripheral blood.
Sequence variations Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line).
Mutation; HGNC; 76; ABL1; Simple; p.Glu255Lys (c.763G>A); ClinVar=VCV000376090; Zygosity=Unspecified (PubMed=21474579).
Disease Chronic myelogenous leukemia, BCR-ABL1 positive (NCIt: C3174)
Chronic myeloid leukemia (ORDO: Orphanet_521)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_0181 (BV-173)
Sex of cell Male
Age at sampling 45Y
Category Cancer cell line
Publications

PubMed=21474579; DOI=10.1158/1078-0432.CCR-11-0234
Nguyen T., Dai Y., Attkisson E., Kramer L., Jordan N., Nguyen N., Kolluri N., Muschen M., Grant S.
HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo.
Clin. Cancer Res. 17:3219-3232(2011)

Cross-references
Cell line collections Kerafast; EVC001
Other Wikidata; Q54798655
Entry history
Entry creation14-Dec-2015
Last entry update20-May-2021
Version number12